Medincell (LTS:0ACH) Total Operating Expense: €40.30 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0ACH Medincell SA LTS:0ACH
78 GF Score
Price €26.88
GF Value €21.95
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Medincell Total Operating Expense?

Medincell LTS:0ACH -0.81% 78 Total Operating Expense is €40.30 Mil as of Mar. 2026. GuruFocus rates LTS:0ACH with a GF Score™ of 78/100 and a GF Value™ of €21.95 (Modestly Overvalued). The stock has 5 warning signs investors should review.

Medincell's Total Operating Expense for the six months ended in Mar. 2026 was €22.08 Mil. Medincell's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €40.30 Mil.

Medincell Total Operating Expense Related Terms

Medincell Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Medincell's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medincell Total Operating Expense Chart

Medincell Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 27.91 33.99 30.14 36.38 40.30

Medincell Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 14.17 16.15 20.23 18.22 22.08
LTS:0ACH
78GF Score
Medincell SA LTS:0ACH
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medincell Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was €40.30 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €40.30 Mil mean?
Medincell (LTS:0ACH) has a Total Operating Expense of €40.30 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Medincell and its competitors.
Is Medincell's Total Operating Expense too high?
Medincell's current Total Operating Expense is €40.30 Mil. Overall, Medincell has a GF Score™ of 78/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medincell's Total Operating Expense compare to VRTX and REGN?
Medincell's Total Operating Expense of €40.30 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Medincell and its competitors. Medincell's current Total Operating Expense is €40.30 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medincell stock overvalued right now?
Based on GuruFocus' analysis, Medincell (LTS:0ACH) is currently considered Modestly Overvalued. The stock's GF Value™ is €21.95, compared to a current price of €26.88 — trading 22.5% above its estimated fair value. The current Total Operating Expense is €40.30 Mil. Medincell's overall GF Score™ is 78/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Medincell (LTS:0ACH), the current Total Operating Expense is €40.30 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medincell (LTS:0ACH) Overvalued in 2026?

Based on GuruFocus' analysis, Medincell stock appears to be overvalued. The current stock price of €26.88 is trading 22.5% above its estimated GF Value™ of €21.95. GuruFocus considers Medincell to be Modestly Overvalued.

Key valuation signals for LTS:0ACH:

  • Total Operating Expense: €40.30 Mil
  • GF Value™: €21.95 vs. price of €26.88 (22.5% above fair value)
  • GF Score™: 78/100 with 5 warning signs

No single metric tells the full story. See the LTS:0ACH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Medincell Business Description

Address 3 rue des Freres Lumiere, Jacou, FRA, 34830
Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.
78GF Score

Get the complete analysis for LTS:0ACH

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.88
Price
€21.95
GF Value